RCKT Q4 2020 Earnings — Rocket Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RCKTRocket Pharmaceuticals, Inc.

$572M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$59M

Net Income

-$61M

EPS (Diluted)

$-1.10

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$28M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$591M

Total Liabilities

$87M

Stockholders' Equity

$504M

Cash & Equivalents

$297M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$59M	-$20M	-201.5%
Net Income	-$61M	-$20M	-206.8%